CBIO
CBIO
KYG2545C1042
Crescent Biopharma, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 85/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±128.1% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors.

Beta (Market Relation)
-
Defensive
Volatility (5Y p.a.)
128.1% p.a.
5-Year Horizon
Max Drawdown (5Y)
-97.8%
5-Year Horizon
Sharpe Ratio
-0.34
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +17.1%
3 Years 146.9% -97.4% -0.38 -52.9%
5 Years 128.1% -97.8% -0.34 -40.6%
10 Years 108.5% -99.7% -0.31 -31.6%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Elevated Short-Term Volatility: 3Y volatility (146.9%) is noticeably higher than the 5Y average (128.1%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (128.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -99.7% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
10 ISS Score: 10 / 10
Audit Risk
8 ISS Score: 8 / 10
Board Risk
6 ISS Score: 6 / 10
Short Ratio
12.25
ende